{"Clinical Trial ID": "NCT00334542", "Intervention": ["INTERVENTION 1:", "- Simvastatin", "Simvastatin 40 mg for 24-28 weeks"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "A history of breast cancer confirmed by histology, meeting 1 of the following criteria:", "In situ ductal carcinoma", "Stage I-III Invasive breast cancer", "At least 3 months after completion of all planned local and systemic treatments, including mastectomy or lumpectomy with or without radiotherapy, adjuvant chemotherapy and/or endocrine treatment", "\u2022 May have refused the recommended treatment provided that all treatment planned/approved by the patient and the attending physician was completed 3 months ago", "At least 1 healthy breast intact", "No prior radiation therapy or mastectomy", "Previous authorised biopsies", "Any hormone-receptor status", "CHARACTERISTICS OF PATIENTS:", "Women", "Pre- or post-menopausal", "ECOG Performance Status 0-2", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective non-hormonal contraception", "No active liver disease", "ASAT and ALT 3 times the upper limit of normal", "creatinine clearance 30 mL/min", "No previous hypersensitivity to a 3-hydroxyl-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase inhibitor or any of its components", "No other concomitant infectious, inflammatory or autoimmune disease (at the discretion of the Principal Investigator)", "THERAPE PRIOR CONCURENT:", "See Disease Characteristics", "No daily consumption of alcohol > 3 standard drinks per day", "A standard drink defined as 10 grams of alcohol, equivalent to 285 mL of beer, 530 mL of light beer, 100 mL of wine or 30 mL of liqueur", "No selective oestrogen receptor modulator or aromatase inhibitor in the last 3 months", "No hormone replacement therapy (HRT) in the last 3 months", "No 5-year-old estrogen and/or anterior progesterone HRT", "Authorized vaginal estrogen preparations", "No concurrent HRT", "No other cholesterol-lowering medicinal product, including a statin, in the last 3 months", "No itraconazole, ketoconazole, nefazodone, cyclosporin, HIV protease inhibitors, clarithromycin, erythromycin, bibefradil, carbamazepine, bosentan, chaparral, amiodarone or verapamil", "No simultaneous daily consumption of grapefruit juice > 8 ounces per day", "No other concomitant agent or therapy to treat or prevent breast cancer in situ or invasive"], "Results": ["Performance measures:", "Change in a group of biomarkers (high-sensibility C-reactive proteins [hsCRP], lipid profile and circulating estrogen) from the base", "[Unspecified]", "Target date: Baseline and week 24", "Results 1:", "Title of the arm/group: Simvastatin", "Description of the arm/group: Simvastatin 40 mg for 24-28 weeks", "Total number of participants analysed: 47", "Median (95% confidence interval)", "Unit of measurement: mg/dl hsCRP: -0.15 (-1 to 0)", "Total Cholesterol: -54 (-58.5 to -39)", "High-density cholesterol (HDL) lipoprotein: -1 (-2 to 3)", "Estrogen (estron sulfate): -81.5 (-225.5 to -40.5)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/50 (0.00 per cent)"]}